Frequency of significant steatosis and compensated advanced chronic liver disease among adults with chronic liver disease

Shahrani, Shahreedhan; Gill, Sandeep Singh; Sooi, Choong Yeong; Skantha, Ruben; Kumar, C Vikneshwaran Chandra; Limun, Mohd Fairul; Affendi, Nik Arsyad Nik Muhamad; Chuah, Kee Huat; Khoo, Stanley; Rajaram, Ruveena Bhavani; Chan, Wah Kheong; Mahadeva, Sanjiv

doi:10.1111/jgh.16313

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 85% of all patients seen in our liver clinic had significant hepatic steatosis. 21 A majority of patients admitted to our ward for cirrhosis and its complications had cryptogenic cirrhosis, which is due to MASLD in most cases. 22 Similarly, cryptogenic cirrhosis as the etiology of hepatocellular carcinoma (HCC) cases seen in our center has more than doubled from 16% to 34% (not including 7% with established diagnosis of MASH) between the time periods of 2006–2009 and 2011–2014.…”

Section: Epidemiology Natural History and Burden Of Diseasementioning

confidence: 95%

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review

Chan,

Chuah,

Rajaram

et al. 2023

Journal of Obesity & Metabolic Syndrome

Self Cite

165

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for steatotic liver disease associated with metabolic syndrome. MASLD is the most common cause of chronic liver disease and is the leading cause of liver-related morbidity and mortality. It is important that all stakeholders be involved in tackling the public health threat of obesity and obesity-related diseases, including MASLD. A simple and clear assessment and referral pathway using non-invasive tests is essential to ensure that patients with severe MASLD are identified and referred to specialist care, while patients with less severe disease remain in primary care, where they are best managed. While lifestyle intervention is the cornerstone of the management of patients with MASLD, cardiovascular disease risk must be properly assessed and managed because cardiovascular disease is the leading cause of mortality. No pharmacological agent has been approved for the treatment of MASLD, but novel anti-hyperglycemic drugs appear to have benefit. Medications used for the treatment of diabetes and other metabolic conditions may need to be adjusted as liver disease progresses to cirrhosis, especially decompensated cirrhosis. Based on non-invasive tests, the concepts of compensated advanced chronic liver disease and clinically significant portal hypertension provide a practical approach to stratifying patients according to the risk of liver-related complications and can help manage such patients. Finally, prevention and management of sarcopenia should be considered in the management of patients with MASLD.

show abstract

Section: Epidemiology Natural History and Burden Of Diseasementioning

confidence: 95%